Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133387) titled 'A Single-Arm, Exploratory, Phase II Clinical Study of Trastuzumab Rezeteccan Combined with Adebrelimab in Locally Advanced or Metastatic Urothelial Carcinoma Resistant to Antibody-Drug Conjugate Combined Immunotherapy' on Sept. 24.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Locally Advanced or Metastatic Urothelial Carcinoma
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-09-24
Target Sample Size: treatment:35;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj...